Patents by Inventor A. Murray Smith
A. Murray Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100024782Abstract: A fuel saving device comprising a support body (10) having at least one flow opening (15) therein and a periphery which adapts the support body (10) for positioning within a sealed environment of a fuel system of a combustion engine in a manner in which the longitudinal axis of the at least one flow opening (15) is coaxial with a fluid flow path, and a plurality of permanent magnets (11-14), the polar axes of all magnets oriented parallel to the flow path through the opening (15), the magnets (11-14) are provided in at least two stacks (16, 16?, each stack (16, 16? containing at least two magnets (11-14), the magnets (11-14) of each stack (16, 16?) each have a polar axis extending in the same direction with the magnets (11-14) of at least one stack (16) having polar axes extending in opposite direction to the other of the at least two stacks (16?).Type: ApplicationFiled: June 20, 2006Publication date: February 4, 2010Inventors: Adrian Menzell, John Kostic, Glenda Shirley Smith, Ian Murray Smith
-
Patent number: 7642254Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 together form, along with the nitrogen atom to which they are attached, an optionally substituted nitrogen containing heterocyclic ring having from 4 to 8 ring atoms; and R3 is selected from hydroxy and —NRN1RN2, where RN1 and RN2 are independently selected from hydrogen, optionally substituted C1-7 alkyl groups, optionally substituted C3-20 heterocyclyl groups and optionally substituted C5-20 aryl groups, or together form, along with the nitrogen atom to which they are attached, an optionally substituted nitrogen containing heterocyclic ring having from 4 to 8 ring atoms, and its use in inhibiting ATM.Type: GrantFiled: February 9, 2006Date of Patent: January 5, 2010Assignee: Kudos Pharmaceuticals LimitedInventors: Marc Geoffrey Hummersone, Keith Allan Menear, Laurent Jean Martin Rigoreau, Graeme Cameron Murray Smith, Niall Morrison Barr Martin, Roger John Griffin
-
Patent number: 7640684Abstract: The present invention is directed to a releasable locking assembly for attaching a wear member to a support structure. It may be used with excavating equipment for attaching ground-engaging teeth to adaptors, lip shrouds to bucket lips, or other analogous uses. The wear member includes at least one pin-retainer-receiving opening in one side. The opening is tapered, being narrower at its outer surface and wider at its inner surface. The support structure includes at least one pin-receiving recess which generally aligns with the opening in the wear member when the wear member and the support structure are operatively coupled. The pin retainer is a frustoconically shaped cylinder which is threaded internally. It is inserted into the opening in the wear member. The wear member is slidably mounted onto the support structure. The pin is an elongate body which is externally threaded. It is screwed into the pin retainer by the application of torque force from a standard ratchet tool.Type: GrantFiled: October 31, 2005Date of Patent: January 5, 2010Assignee: Esco CorporationInventors: Dwight L. Adamic, Murray Smith
-
Publication number: 20090163477Abstract: A compound of formula (I): for use in treating cancer or other diseases ameliorated by the inhibition of PARP, wherein: A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X?NRX then n is 1 or 2 and if X?CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are independently selected from the group consisting of hydrogen and C1-4 alkyl, or when X is CRXRY, RC1, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; R1 is selected from H and halo; and Het is selected from: where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N, where only one or two of Y1, Y2 and Y3 can be N;Type: ApplicationFiled: June 20, 2008Publication date: June 25, 2009Inventors: Muhammad Hashim Javaid, Graeme Cameron Murray Smith, Niall Morrison Barr Martin, Sylvie Gomez, Vincent Junior Ming-lai Loh, Xiao-Ling Fan Cockcroft, Stefano Forte, Keith Allan Menear, Ian Timothy William Matthews, Frank Kerrigan
-
Publication number: 20090117248Abstract: A method of producing a pasta filata cheese product, such as a Mozzarella-type cheese, in a continuous process without emulsifier or pH regulator additives requires preparing a typical pasta filata-type cheese curd and supplying the curd in cut pieces to one end of a processing chamber (14). The chamber (14) has an agitator (18) which rotates to work, knead, stretch and move the curd through the chamber. At the same time, steam is injected into the curd in the chamber through a plurality of injection nozzles (23) spaced along the length of the chamber (14) to heat and cook the cheese while it is simultaneously mechanically worked. The cooked product exiting from the chamber (14) is moulded to a desired shape.Type: ApplicationFiled: September 5, 2005Publication date: May 7, 2009Applicant: Gold Peg International Pty LtdInventors: Robert Murray Smith, Alastair Graeme Sorley, Mark Wynn Kirkby
-
Patent number: 7504397Abstract: Compounds of formula I: A-B-C??(I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof are provided, wherein variables A, B and C are defined herein and wherein such compounds act as mTor inhibitors.Type: GrantFiled: February 24, 2006Date of Patent: March 17, 2009Assignee: Kudos Pharmaceuticals Ltd.Inventors: Marc Geoffrey Hummersone, Sylvie Gomez, Keith Allan Menear, Xiao-Ling Fan Cockcroft, Graeme Cameron Murray Smith
-
Publication number: 20090069303Abstract: A compound of the formula (I): wherein: A and B together represent an optionally substituted, fused aromatic ring; D is selected from: (i) where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N; and (ii) where Q is O or S; RD is: wherein RN1 is selected from H and optionally substituted C1-10 alkyl; X is selected from a single bond, NRN2, CRC3RC4 and C?O; RN2 is selected from H and optionally substituted C1-10 alkyl; RC3 and RC4 are independently selected from H, R, C(?O)OR, where R is optionally substituted C1-10 alkyl, optionally substituted C5-20 aryl or optionally substituted C3-20 heterocyclyl; Y is selected from NRN3 and CRC1RC2.Type: ApplicationFiled: November 14, 2008Publication date: March 12, 2009Applicant: MAYBRIDGE LIMITEDInventors: Muhammad Hashim Javaid, Keith Allan Menear, Sylvie Gomez, Marc Geoffrey Hummersone, Niall Morrison Barr Martin, Graeme Cameron Murray Smith, Xiao-Ling Fan Cockcroft, Frank Kerrigan
-
Publication number: 20090043091Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and RN1 is selected from hydrogen, an optionally substituted C1-7 alkyl group, an optionally substituted C3-20 heterocyclyl group, an optionally substituted C5-20 aryl group, an acyl group, an ester group and an amido group, and its use as a pharmaceutical.Type: ApplicationFiled: September 19, 2008Publication date: February 12, 2009Applicant: KUDOS PHARMACEUTICALS LIMITEDInventors: Graeme Cameron Murray Smith, Niall Morrison Barr Martin, Xiao-Ling Fan Cockcroft, Ian Timothy Williams Matthews, Keith Allan Menear, Laurent Jean Martin Rigoreau, Marc Geoffrey Hummersone, Roger John Griffin
-
Publication number: 20090035394Abstract: This invention relates to the finding that inhibition of the catalytic subunit of DNA protein kinase (DNA-PKcs) increases the sensitivity of cancer cells that display an ATM deficient phenotype to DNA damaging therapies, such as irradiation or chemotherapy. Methods of treating cancers displaying an ATM deficient phenotype and methods of determining the susceptibility of a patient to such methods are provided.Type: ApplicationFiled: May 26, 2006Publication date: February 5, 2009Inventors: Graeme Cameron Murray Smith, Andrew James Slade, Caroline Jane Richardson, Barbara Wanda Durkacz
-
Publication number: 20090023727Abstract: A compound of the formula (I): wherein: R represents one or more optional substituents on the fused cyclohexene ring; X can be NRX or CRXRY; if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1; if X=NRX, then RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, optionally substituted C5-20 aryl, optionally substituted C3-20 heterocyclyl, optionally substituted amido, optionally substituted thioamido, optionally substituted ester, optionally substituted acyl, and optionally substituted sulfonyl groups; if X=CRXRY then RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, optionally substituted C5-20 aryl, optionally substituted C3-20 heterocyclyl, optionally substituted amido, optionally substituted thioamido, optionally substituted sulfonamino, optionally substituted ether, optionally substituted ester, optionally substituted acyl, optionally substituted acylamido, and optionally substituted sulfonyl groups and RY is selected from H, hydroxy, optType: ApplicationFiled: July 3, 2008Publication date: January 22, 2009Inventors: Muhammad Hashim Javaid, Keith Allan Menear, Niall Morrison Barr Martin, Graeme Cameron Murray Smith, David Alan Rudge, Craig Anthony Roberts
-
Patent number: 7470688Abstract: A compound of the formula (I): wherein: A and B together represent an optionally substituted, fused aromatic ring; D is selected from: (i) where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N; and (ii) where Q is O or S; RD is: wherein RN1 is selected from H and optionally substituted C1-10 alkyl; X is selected from a single bond, NRN2, CRC3RC4 and C?O; RN2 is selected from H and optionally substituted C1-10 alkyl; RC3 and RC4 are independently selected from H, R, C(?O)OR, where R is optionally substituted C1-10 alkyl, optionally substituted C5-20 aryl or optionally substituted C3-20 heterocyclyl; Y is selected from NRN3 and CRC1RC2; RC1 and RC2 are independently selected from H, R, C(?O)OR, where R is optionally substituted C1-10 alkyl, optionally substituted C5-20 aryl or optionally substituted C3-20 heterocyclyl; RC1 and RC2 together with the carbon atom to which they are attached may form an optionally substituted spiro-Type: GrantFiled: October 17, 2006Date of Patent: December 30, 2008Assignee: Maybridge LimitedInventors: Muhammad Hashim Javaid, Keith Allan Menear, Sylvie Gomez, Marc Geoffrey Hummersone, Niall Morrison Barr Martin, Graeme Cameron Murray Smith, Xiao-Ling Fan Cockcroft, Frank Kerrigan
-
Publication number: 20080242664Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is —NH—C(?O)— or —O—; Y is an optionally substituted C1-5 alkylene group; X is selected from SR3 or NR4R5, wherein, R3, or R4 and R5 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R4 and R5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is —O—, X is additionally selected from —C(?O)—NR6R7, wherein R6 and R7 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groType: ApplicationFiled: June 5, 2008Publication date: October 2, 2008Applicants: KUDOS PHARMACEUTICALS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Graeme Cameron Murray Smith, Niall Morrison Barr Martin, Keith Allan Menear, Marc Geoffrey Hummersone, Laurent Jean Martin Rigoreau, Roger John Griffin, Bernard Thomas Golding, David Richard Newell, Hilary Alan Calvert, Nicola Jane Curtin, Ian Robert Hardcastle, Kappusamy Saravanan
-
Patent number: 7429660Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and RN1 is selected from hydrogen, an optionally substituted C1-7 alkyl group, an optionally substituted C3-20 heterocyclyl group, an optionally substituted C5-20 aryl group, an acyl group, an ester group and an amido group, and its use as a pharmaceutical.Type: GrantFiled: August 13, 2004Date of Patent: September 30, 2008Assignee: Kudos Pharmaceuticals LimitedInventors: Graeme Cameron Murray Smith, Niall Morrison Barr Martin, Xiao-Ling Fan Cockcroft, Ian Timothy Williams Matthews, Keith Allan Menear, Laurent Jean Martin Rigoreau, Marc Geoffrey Hummersone, Roger John Griffin
-
Publication number: 20080194546Abstract: There is provided a compound of formula I: wherein: one or two of X5, X6 and X8 is N, and the others are CH; R7 is selected from halo, ORO1, SRS1, NRN1RN2, NRN7aC(?O)RC1, NRN7bSO2RS2a, an optionally substituted C5-20 heteroaryl group, or an optionally substituted C5-20 aryl group, where RO1 and RS1 are selected from H, an optionally substituted C5-20 aryl group, an optionally substituted C5-20 heteroaryl group, or an optionally substituted C1-7 alkyl group; RN1 and RN2 are independently selected from H, an optionally substituted C1-7 alkyl group, an optionally substituted C5-20 heteroaryl group, an optionally substituted C5-20 aryl group or RN1 and RN2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; RC1 is selected from H, an optionally substituted C5-20 aryl group, an optionally substituted C5-20 heteroaryl group, an optionally substituted C1-7 alkyl group or NRN8RN9, where RN8 and RN9 are independently selected from H, an optionally subsType: ApplicationFiled: August 21, 2007Publication date: August 14, 2008Applicant: KuDOS Pharmaceuticals LimitedInventors: Marc Geoffrey Hummersone, Gomez Sylvie, Keith Allan Menear, Graeme Cameron Murray Smith, Karine Malagu, Heather Mary Ellen Duggan, Niall Morrison Barr Martin, Frederic Georges Marie Leroux, Gesine Johanna Hermann, Xiao-Ling Fan Cockcroft
-
Patent number: 7407957Abstract: A compound of formula (I): for use in treating cancer or other diseases ameliorated by the inhibition of PARP, wherein: A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are independently selected from the group consisting of hydrogen and C1-4 alkyl, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; R1 is selected from H and halo; and Het is selected from: where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N, where only one or two of Y1, Y2 and Y3 can be N; andType: GrantFiled: August 26, 2005Date of Patent: August 5, 2008Assignees: Maybridge Limited, Kudos Pharmaceuticals LimitedInventors: Muhammad Hashim Javaid, Graeme Cameron Murray Smith, Naill Morrison Barr Martin, Sylvie Gomez, Vincent Junior Ming-lai Loh, Xiao-Ling Fan Cockcroft, Stefano Forte, Keith Allan Menear, Ian Timothy William Matthews, Frank Kerrigan
-
Patent number: 7402607Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is —NH—C(?O)— or —O—; Y is an optionally substituted C1-5 alkylene group; X is selected from SR3 or NR4R5, wherein, R3, or R4 and R5 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R4 and R5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is —O—, X is additionally selected from —C(?O)—NR6R7, wherein R6 and R7 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclylType: GrantFiled: September 20, 2005Date of Patent: July 22, 2008Assignees: Kudos Pharmaceuticals Limited, Cancer Research Technology LimitedInventors: Graeme Cameron Murray Smith, Niall Morrison Barr Martin, Keith Allan Menear, Marc Geoffrey Hummersone, Laurent Jean Martin Rigoreau, Roger John Griffin, Bernard Thomas Golding, David Richard Newell, Hilary Alan Calvert, Nicola Jane Curtin, Ian Robert Hardcastle, Kappusamy Saravanan
-
Publication number: 20080148608Abstract: A ground engaging tool system comprises a ground engaging tool such as a tip, an adapter mounted to or part of a work tool, and a rotating lock member. The ground engaging tool is attached to the adapter, and a post portion of the adapter slides into a slot provided on the lock. The lock is rotated so that the entrance to the slot is blocked and the post cannot slide out of the slot. The lock in this position is in a locking position, and the retention of the post in the slot of the lock retains the ground engaging tool to the adapter.Type: ApplicationFiled: August 16, 2007Publication date: June 26, 2008Inventors: Craig Harder, Murray Smith
-
Patent number: 7226918Abstract: The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R1 and R2 are independently hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR4 and O, O and CR?4 and NR?4 and N, where the unsaturation is in the appropriate place in the ring, and where one of R3 and R4 or R?4 is an optionally substituted C3-20 heteroaryl or C5-20 aryl group, and the other of R3 and R4 or R?4 is H, or R3 and R4 or R?4 together are -A-B—, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM.Type: GrantFiled: August 14, 2002Date of Patent: June 5, 2007Assignee: Cancer Research Technology LimitedInventors: Niall Morrison Barr Martin, Graeme Cameron Murray Smith, Roger John Griffin, Bernard Thomas Golding, Ian Robert Hardcastle, David Richard Newell, Hilary Alan Calvert, Nicola Jane Curtin, Laurent Jean Martin Rigoreau, Xiao-ling Fan Cockcroft, Vincent Junior Ming-lai Loh, Paul Workman, Florence Irene Raynaud, Bernard Paul Nutley
-
Patent number: 7196085Abstract: A compound of formula: or an isomer, salt, solvate, chemically protected form, or prodrug thereof, wherein A and B together represent an optionally substituted, fused aromatic ring; RL is a C5-7 aryl group substituted in the meta position by the group R2, and optionally further substituted; wherein R2 is selected from: and its use as a pharmaceutical, in particular for the treatment of diseases ameliorated by inhibiting the activity of PARP.Type: GrantFiled: April 29, 2003Date of Patent: March 27, 2007Assignees: KuDOS Pharmaceuticals Limited, Maybridge plcInventors: Niall Morrison Barr Martin, Graeme Cameron Murray Smith, Penny Jane Eversley, Xiao-Ling Cockcroft, Frank Kerrigan, Janet Hoare, Lesley Dixon
-
Patent number: 7151102Abstract: A method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula: or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein: A and B together represent an optionally substituted, fused aromatic ring; RC is represented by —L—RL, where L is of formula: —(CH2)n1-Qn2-(CH2)n3— wherein n1, n2 and n3 are each selected from 0, 1, 2 and 3, the sum of n1, n2 and n3 is 1, 2 or 3 and Q is selected from O, S, NH, C(?O) or —CR1R2—, where R1 and R2 are independently selected from hydrogen, halogen or optionally substituted C1-7 alkyl, or may together with the carbon atom to which they are attached form a C3-7 cyclic alkyl group, which may be saturated (a C3-7 cycloalkyl group) or unsaturated (a C3-7 cycloalkenyl group), or one of R1 and R2 may be attached to an atom in RL to form an unsaturated C3-7 cycloalkenyl group which comprises the carbon atoms to which R1 and R2 are aType: GrantFiled: October 30, 2001Date of Patent: December 19, 2006Assignees: Kudos Pharmaceuticals Limited, Maybridge PLCInventors: Niall Morrison Barr Martin, Graeme Cameron Murray Smith, Charles Richard White, Roger Frank Newton, Diane Gillian Douglas, Penny Jane Eversley, Julia Vile